Cipla's $120-150M Lanreotide Product Faces Extended U.S. Recall, Resupply Unlikely
Cipla is experiencing a significant regulatory challenge with the Class II recall of its Lanreotide injection in the U.S. market, which Nomura identifies as one of the company's top American products generating $120-150 million in annual sales. The situation has worsened with the assessment that resupply is unlikely in H1 FY27, suggesting complex quality issues that require extensive remediation efforts.
*this image is generated using AI for illustrative purposes only.
Cipla is facing significant regulatory and financial challenges in the United States as Nomura reports a full Class II recall of the company's Lanreotide injection, a product that represents one of the pharmaceutical giant's most valuable U.S. assets with estimated annual sales of $120-150 million.
Financial Impact of the Recall
The recall carries substantial financial implications for Cipla's U.S. operations. According to Nomura's analysis, the affected Lanreotide injection ranks among the company's top-performing products in the American market.
| Product Details: | Information |
|---|---|
| Product Name: | Lanreotide Injection |
| Annual Sales Estimate: | $120-150 Million |
| Market Ranking: | Top U.S. Product |
| Recall Classification: | Class II |
| Expected Resupply: | Unlikely in H1 FY27 |
Extended Supply Disruption
The situation has become more concerning with Nomura's assessment that resupply of the product in H1 FY27 now seems unlikely. This extended timeline suggests that the quality issues prompting the recall are more complex than initially anticipated and may require comprehensive remediation efforts.
Understanding Class II Recalls
Class II recalls represent a significant regulatory action in the pharmaceutical industry. These recalls are typically initiated when there is a reasonable probability that the use of or exposure to a violative product will cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Market Position and Operational Challenges
The recall of such a high-revenue product underscores the operational challenges facing Cipla's U.S. business segment. The extended timeline for potential resupply indicates that the company must address fundamental quality control issues before the product can return to the market.
This development represents a notable setback for Cipla's U.S. operations, affecting both immediate revenue streams and longer-term market positioning in the competitive American pharmaceutical landscape.
Historical Stock Returns for Cipla
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.60% | -0.76% | -1.03% | -16.40% | -9.49% | +63.32% |
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
